- Home
- PMCB vs IMRN Comparison
PMCB vs IMRN Comparison
Compare PMCB & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMCB
- IMRN
- Stock Information
- Founded
- PMCB 1996
- IMRN 1994
- Country
- PMCB United States
- IMRN Australia
- Employees
- PMCB N/A
- IMRN N/A
- Industry
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- PMCB Health Care
- IMRN Health Care
- Exchange
- PMCB Nasdaq
- IMRN Nasdaq
- Market Cap
- PMCB 6.6M
- IMRN 14.4M
- IPO Year
- PMCB N/A
- IMRN N/A
- Fundamental
- Price
- PMCB $0.93
- IMRN $1.90
- Analyst Decision
- PMCB
- IMRN
- Analyst Count
- PMCB 0
- IMRN 0
- Target Price
- PMCB N/A
- IMRN N/A
- AVG Volume (30 Days)
- PMCB 50.1K
- IMRN 93.9K
- Earning Date
- PMCB 12-12-2025
- IMRN 08-29-2025
- Dividend Yield
- PMCB N/A
- IMRN N/A
- EPS Growth
- PMCB N/A
- IMRN N/A
- EPS
- PMCB 0.01
- IMRN N/A
- Revenue
- PMCB N/A
- IMRN $4,777,422.00
- Revenue This Year
- PMCB N/A
- IMRN N/A
- Revenue Next Year
- PMCB N/A
- IMRN N/A
- P/E Ratio
- PMCB $147.76
- IMRN N/A
- Revenue Growth
- PMCB N/A
- IMRN 48.63
- 52 Week Low
- PMCB $0.80
- IMRN $1.50
- 52 Week High
- PMCB $2.03
- IMRN $2.48
- Technical
- Relative Strength Index (RSI)
- PMCB 40.16
- IMRN 37.34
- Support Level
- PMCB $0.92
- IMRN $2.09
- Resistance Level
- PMCB $1.03
- IMRN $2.24
- Average True Range (ATR)
- PMCB 0.04
- IMRN 0.13
- MACD
- PMCB -0.01
- IMRN -0.04
- Stochastic Oscillator
- PMCB 8.26
- IMRN 17.24
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.